Zacks Investment Management purchased a new position in Heska Corporation (NASDAQ:HSKA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,411 shares of the medical research company’s stock, valued at approximately $654,000. Zacks Investment Management owned about 0.09% of Heska Corporation at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of HSKA. Vanguard Group Inc. lifted its holdings in shares of Heska Corporation by 47.0% during the 1st quarter. Vanguard Group Inc. now owns 350,609 shares of the medical research company’s stock worth $36,807,000 after acquiring an additional 112,115 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Heska Corporation by 115.5% in the second quarter. Dimensional Fund Advisors LP now owns 120,174 shares of the medical research company’s stock worth $12,266,000 after acquiring an additional 64,418 shares in the last quarter. Geneva Advisors LLC grew its position in Heska Corporation by 565.4% in the second quarter. Geneva Advisors LLC now owns 75,499 shares of the medical research company’s stock worth $7,706,000 after acquiring an additional 64,153 shares in the last quarter. Principal Financial Group Inc. purchased a new position in Heska Corporation in the first quarter worth $5,234,000. Finally, Marshall Wace North America L.P. purchased a new position in Heska Corporation in the second quarter worth $4,847,000. Hedge funds and other institutional investors own 81.36% of the company’s stock.

In other news, CFO John Mcmahon sold 2,608 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total value of $263,851.36. Following the completion of the sale, the chief financial officer now directly owns 193 shares of the company’s stock, valued at approximately $19,525.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Nancy Wisnewski sold 825 shares of Heska Corporation stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $102.21, for a total value of $84,323.25. Following the completion of the transaction, the executive vice president now owns 38,114 shares of the company’s stock, valued at approximately $3,895,631.94. The disclosure for this sale can be found here. Company insiders own 14.70% of the company’s stock.

Heska Corporation (NASDAQ HSKA) opened at 89.44 on Wednesday. The firm has a 50-day moving average price of $94.97 and a 200-day moving average price of $98.39. The stock has a market capitalization of $646.29 million, a PE ratio of 45.59 and a beta of 0.84. Heska Corporation has a 52 week low of $46.51 and a 52 week high of $115.00.

Heska Corporation (NASDAQ:HSKA) last posted its earnings results on Thursday, August 3rd. The medical research company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $34.30 million for the quarter, compared to the consensus estimate of $33.35 million. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.35 EPS. Equities research analysts predict that Heska Corporation will post $2.04 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/10/04/6411-shares-in-heska-corporation-hska-purchased-by-zacks-investment-management.html.

HSKA has been the subject of several research analyst reports. Zacks Investment Research raised Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 price target for the company in a research note on Friday, August 4th. BidaskClub downgraded Heska Corporation from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Aegis boosted their target price on Heska Corporation from $114.50 to $129.50 and gave the stock a “buy” rating in a research report on Tuesday, August 1st. Benchmark Co. upped their target price on Heska Corporation from $106.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, B. Riley reaffirmed a “neutral” rating and issued a $85.00 target price on shares of Heska Corporation in a research note on Friday, July 28th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $105.20.

Heska Corporation Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corporation (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska Corporation (NASDAQ:HSKA)

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.